NCT07242105 Optimizing Brain Excitability in Depression
| NCT ID | NCT07242105 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Major Depressive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 145 participants |
| Start Date | 2025-10-23 |
| Primary Completion | 2029-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 145 participants in total. It began in 2025-10-23 with a primary completion date of 2029-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to improve depression treatment by establishing reliable prefrontal excitability markers through Targeting with Automated Real-time Guidance for Enhancing TEPs (TARGET).
Eligibility Criteria
Inclusion Criteria: * Men and women, ages 18 to 65 * Diagnosis of major depressive disorder, assessed through a Structured Clinical Interview for DSM-5 (SCID-5) * In a current depressive episode, assessed through a Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (SCID-5) * Moderate-to-severe depression as indicated by a score between 11-20 on the Quick Inventory of Depressive Symptoms (QIDS) * Must comprehend English well to ensure adequate comprehension of the EEG and TMS instructions, and of clinical scales * No current or history of neurological disorders * No seizure disorder or risk of seizures * Neurosurgical patients: Men and women ages 18-65 with medication-refractory epilepsy who are admitted for phase II intracranial monitoring to detect a seizure focus will be considered appropriate for this study. Participants must have the intellectual capacity to understand the consent process and agree to the study. Exclusion Criteria: * Those with a contraindication for MRIs (e.g. implanted metal) * History of head trauma with loss of consciousness * History of seizures or on medications that reduce seizure threshold (e.g., olanzapine, chlorpromazine, lithium) * Neurological or uncontrolled medical disease * Any unstable medical condition * Active substance abuse * Diagnosis of psychotic or bipolar disorder * A prior history of Electroconvulsive Therapy (ECT) failure * History of suicide attempt in the past year * Currently pregnant or breastfeeding * Repetitive Transcranial Magnetic Stimulation (rTMS) treatment in the past six months
Contact & Investigator
Corey J Keller, MD, PhD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT07242105 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Major Depressive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07242105 currently recruiting?
Yes, NCT07242105 is actively recruiting participants. Contact the research team at kellerlab@stanford.edu for enrollment information.
Where is the NCT07242105 trial being conducted?
This trial is being conducted at Iowa City, United States, Stanford, United States.
Who is sponsoring the NCT07242105 clinical trial?
NCT07242105 is sponsored by Stanford University. The principal investigator is Corey J Keller, MD, PhD at Stanford University. The trial plans to enroll 145 participants.